2Morrow is a leader in digital behavioral health, providing evidence-based health and wellness programs to some of the nation's largest employers, states, and health plans. Founded in 2011 by a nurse and a medical device engineer, 2Morrow's vision is to increase access to care by combining behavioral science and smartphone technology. 2Morrow has helped over half a million people improve their lives using our digital health programs. At 2Morrow, evidence is part of our DNA. With over 20 studies and one of the few Phase III clinical trials in digital health, 2Morrow continues to be a the forefront of the emerging digital health and digital therapeutic industry.

4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our coveted genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology.

Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain. Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology.

Aevice Health provides non-invasive wearable technology that enables real-time monitoring of respiratory health. The devices facilitate early detection of cardiopulmonary issues and allow clinicians to track patient responses to treatment effectively. This approach enhances patient care by delivering critical insights directly from home.

Aksense is developing a quick blood test to help people who are suffering from healthcare-associated infections, with testing these infections in one minute with a portable electronic biosensor, without a lab or expert, saving lives, time, and money. Contact us to find out more.

Alva Health is a Yale technology startup that is developing a wearable neuromonitoring platform with the first indication in real-time stroke detection, for payers that provide healthcare coverage to populations with high incidence of cardiovascular disease and stroke. Alva Health recently raised $1.5MM in non-dilutive funding from the National Science Foundation and National Institutes of Health SBIR programs to develop their pre-production device. Their founders have a track record of inventing and validating neurotechnologies through the FDA, as well as B2B sales in the medical device industry, and they were named one of the Top 50 MedTech startups worldwide in 2021 by MedTech Innovator.

Ankr recreates your brick-and-mortar clinic infrastructure including front desk, MA, scribe, and answering service in the cloud, so that your doctors can perform billable visits anywhere, anytime. Ankr is an Epic(R) and eClinicalWorks(R) Vendor Services partner and Athena(R) marketplace-certified vendor. Talk to us today to see why organizations across USA trust Ankr to increase revenue and quality of after-hours care!

Anumana is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments.

Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies for biomedical research, diagnostics, and therapeutic applications.

Astek Diagnostics develops a platform that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It employs a single-use cartridge to identify bacterial infection in the urine in substantially less time by detecting the oxygen consumption of bacterial species.

Atom Bioworks is a developer of a pattern-recognition enabled DNA-antibody-mimic rational design platform for sensing and therapeutics of infectious diseases.